GRCL — Gracell Biotechnologies Income Statement
0.000.00%
Last trade - 00:00- $972.69m
- $750.11m
- 49
- 23
- 90
- 54
Annual income statement for Gracell Biotechnologies, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.366 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 62.5 | 147 | 214 | 464 | 625 |
| Operating Profit | -62.5 | -147 | -214 | -464 | -625 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -60.8 | -139 | -212 | -452 | -607 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -60.8 | -139 | -212 | -452 | -608 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -60.8 | -139 | -212 | -452 | -608 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -73 | -201 | -275 | -454 | -608 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.223 | -0.613 | -0.838 | -1.38 | -1.8 |